JP2015511721A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511721A5
JP2015511721A5 JP2015502555A JP2015502555A JP2015511721A5 JP 2015511721 A5 JP2015511721 A5 JP 2015511721A5 JP 2015502555 A JP2015502555 A JP 2015502555A JP 2015502555 A JP2015502555 A JP 2015502555A JP 2015511721 A5 JP2015511721 A5 JP 2015511721A5
Authority
JP
Japan
Prior art keywords
level
cells
blood sample
cd11b
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015502555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511721A (ja
JP6276252B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2013/050277 external-priority patent/WO2013144957A1/en
Publication of JP2015511721A publication Critical patent/JP2015511721A/ja
Publication of JP2015511721A5 publication Critical patent/JP2015511721A5/ja
Application granted granted Critical
Publication of JP6276252B2 publication Critical patent/JP6276252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015502555A 2012-03-26 2013-03-21 アルツハイマー病の診断のための細胞マーカーおよびアルツハイマー病の進行の細胞マーカー Active JP6276252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615465P 2012-03-26 2012-03-26
US61/615,465 2012-03-26
PCT/IL2013/050277 WO2013144957A1 (en) 2012-03-26 2013-03-21 Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression

Publications (3)

Publication Number Publication Date
JP2015511721A JP2015511721A (ja) 2015-04-20
JP2015511721A5 true JP2015511721A5 (enExample) 2016-05-12
JP6276252B2 JP6276252B2 (ja) 2018-02-07

Family

ID=49258360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502555A Active JP6276252B2 (ja) 2012-03-26 2013-03-21 アルツハイマー病の診断のための細胞マーカーおよびアルツハイマー病の進行の細胞マーカー

Country Status (10)

Country Link
US (1) US20150057176A1 (enExample)
EP (1) EP2831584B1 (enExample)
JP (1) JP6276252B2 (enExample)
KR (1) KR20140145173A (enExample)
CN (1) CN104471394B (enExample)
AU (1) AU2013239070A1 (enExample)
CA (1) CA2907909A1 (enExample)
ES (1) ES2819174T3 (enExample)
IL (1) IL234779A (enExample)
WO (1) WO2013144957A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6312302B2 (ja) * 2014-01-06 2018-04-18 公益財団法人ヒューマンサイエンス振興財団 脳梗塞の診断マーカー
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング,インコーポレイテッド Tim-3とそのリガンドとの相互作用の遮断によるがん治療
JP6499342B2 (ja) * 2018-03-19 2019-04-10 隆樹 日和佐 脳梗塞の診断マーカー
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
WO2020198299A1 (en) * 2019-03-26 2020-10-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for characterizing and treating alzheimer's disease
CN111727260A (zh) * 2019-10-15 2020-09-29 湖南乾康科技有限公司 中间型单核细胞在制备诊断和预测ad药物中的应用
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング,インコーポレイテッド ガレクチン-3を遮断することにより炎症性疾患を処置する方法
CN112562867A (zh) * 2021-02-22 2021-03-26 天津迈德新医药科技有限公司 一种预测极早期hiv感染风险的装置、存储介质和电子装置
CA3228621A1 (en) 2021-08-09 2023-02-16 Xin Huang Compositions, kits, and methods for detecting preclinical alzheimer's disease
US20250009714A1 (en) * 2021-11-02 2025-01-09 Tranquis Therapeutics, Inc. Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype
KR102745500B1 (ko) * 2022-09-02 2024-12-23 한양대학교 에리카산학협력단 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법
CN116270741B (zh) * 2023-02-28 2025-10-24 东莞市东南部中心医院 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302020T1 (de) * 2000-01-20 2005-09-15 Yeda Res & Dev Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
US20020137108A1 (en) * 2000-11-08 2002-09-26 Michael Mullan CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease
AU2002353486B2 (en) * 2001-12-06 2009-01-15 Yeda Research And Development Co. Ltd Vaccine and method for treatment of motor neurone diseases
CN100591761C (zh) * 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
WO2010033861A1 (en) * 2008-09-18 2010-03-25 Cedars-Sinai Medical Center Optical method for the detection of alzheimer's disease
JP5904953B2 (ja) * 2010-03-10 2016-04-20 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Alsの早期診断およびals進行のための細胞性血液マーカー

Similar Documents

Publication Publication Date Title
JP2015511721A5 (enExample)
Zucchi et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers
Ting et al. Biomarkers of diabetic retinopathy
JP2018505658A5 (enExample)
JP2016500110A5 (enExample)
JP2015505370A5 (enExample)
JP2015530877A5 (enExample)
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
JP2014144959A5 (enExample)
JP2017184729A5 (enExample)
MX2018009304A (es) Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.
WO2018007872A9 (en) Biomarkers for inflammatory bowel disease
JP2014512006A5 (enExample)
EP2532748A3 (en) DNA aptamer specifically binding to human cardiac troponin I
GB201014837D0 (en) Biomarker signatures and uses thereof
Kjær et al. The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients
NZ774381A (en) Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy
CY1119797T1 (el) Λακτοφερινη για χρηση στη διαγνωση και προγνωση της νοσου alzheimer
JP2018529931A5 (enExample)
JP2013522589A5 (enExample)
Martinez-Martin et al. Measurement of nonmotor symptoms in clinical practice
Postupna et al. Cerebral cortical Aβ 42 and PHF-τ in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE
MX2018015140A (es) Firmas de biomarcadores de lupus eritematoso sistemico y sus usos.
Agosto‐Burgos et al. The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis
WO2017211893A8 (en) Biomarker signatures of systemic lupus erythematosus and uses thereof